First-Pass Elimination Basic Concepts and Clinical Consequences
暂无分享,去创建一个
[1] T. Walle,et al. Food‐induced increase in propranolol bioavailability—Relationship to protein and effects on metabolites , 1981, Clinical pharmacology and therapeutics.
[2] J. Kanto,et al. Effect of food on the bioavailability of labetalol. , 1980, British journal of clinical pharmacology.
[3] W. Wagner,et al. Sublingual and oral administration of methyltestosterone. A comparison of drug bioavailability. , 1973, The Journal of clinical pharmacology and new drugs.
[4] K. Diem. Documenta Geigy Scientific Tables , 1970 .
[5] M. Rowland,et al. Influence of route of administration on drug availability. , 1972, Journal of pharmaceutical sciences.
[6] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[7] L. Gram,et al. First‐pass metabolism of imipramine in man , 1975, Clinical pharmacology and therapeutics.
[8] D. Breimer,et al. Rectal Drug Administration , 1982, Clinical pharmacokinetics.
[9] C. Bahr,et al. Contribution of 4‐hydroxy‐alprenolol to adrenergic beta receptor blockade of alprenolol , 1979, Clinical pharmacology and therapeutics.
[10] P. Neuvonen,et al. Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. , 1978, British medical journal.
[11] R. Branch. Drugs as Indicators of Hepatic Function , 2007, Hepatology.
[12] G Levy,et al. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient , 1980, Clinical pharmacology and therapy.
[13] K. Giacomini,et al. Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt , 1980, Clinical pharmacology and therapeutics.
[14] C. T. Ueda,et al. Absolute quinidine bioavailability , 1976, Clinical pharmacology and therapeutics.
[15] L. Bertilsson,et al. Nortriptyline formation after single oral and intramuscular doses of amitriptyline , 1982, Clinical pharmacology and therapeutics.
[16] H. Just,et al. Lorcainide; I. Saturable presystemic elimination , 1979, Clinical pharmacology and therapeutics.
[17] L. Paalzow,et al. Morphine kinetics in cancer patients , 1981, Clinical pharmacology and therapeutics.
[18] P. Meffin,et al. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. , 1979, Gastroenterology.
[19] R. G. Mcallister,et al. The Pharmacology of Verapamil , 1983 .
[20] O. Drummer,et al. Fluorouracil Therapy in Patients with Carcinoma of the Large Bowel: A Pharmacokinetic Comparison of Various Rates and Routes of Administration , 1978, Clinical pharmacokinetics.
[21] R. Branch,et al. Meperidine disposition in man: Influence of urinary pH and route of administration , 1981, Clinical pharmacology and therapeutics.
[22] S. Keiding,et al. Effect of sinusoidal perfusion on galactose elimination kinetics in perfused rat liver. , 1978, The Journal of pharmacology and experimental therapeutics.
[23] R. Branch,et al. The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration , 1978, Clinical pharmacokinetics.
[24] J. W. Findlay,et al. Codeine kinetics as determined by radioimmunoassay , 1977, Clinical pharmacology and therapeutics.
[25] P. Armstrong,et al. Rapid disappearance of nitroglycerin following incubation with human blood. , 1980, Canadian journal of physiology and pharmacology.
[26] T. Ludden,et al. Clinical Pharmacokinetics of Hydralazine , 1982, Clinical pharmacokinetics.
[27] D. Scott,et al. Pharmacokinetics of lidocaine in man , 1971, Clinical pharmacology and therapeutics.
[28] M. Ehrnebo,et al. Bioavailability and first‐pass metabolism of oral pentazocine in man , 1977, Clinical pharmacology and therapeutics.
[29] J. Schou,et al. d‐Propoxyphene kinetics after single oral and intravenous doses in man , 1979, Clinical pharmacology and therapeutics.
[30] G. Jennings,et al. Low oral bioavailability of dihydroergotamine and first‐pass extraction in patients with Orthostatic hypotension , 1981, Clinical pharmacology and therapeutics.
[31] R. Schneider,et al. β-Blocker Plasma Concentrations and Inflammatory Disease , 1982 .
[32] C. Klaassen,et al. First-pass effect of morphine in rats. , 1977, The Journal of pharmacology and experimental therapeutics.
[33] C. Bahr,et al. Influence of pentobarbital on effect and plasma levels of alprenolol and 4‐hydroxy‐alprenolol , 1979, Clinical pharmacology and therapeutics.
[34] J. Oates,et al. Plasma propranolol levels in adults With observations in four children , 1970, Clinical pharmacology and therapeutics.
[35] T. Winsor. Plethysmographic comparison of sublingual and intramuscular ergotamine , 1981, Clinical pharmacology and therapeutics.
[36] L. Hellman,et al. Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. , 1973, The Journal of pharmacology and experimental therapeutics.
[37] A. Melander,et al. Enhancement of the bioavailability of propranolol and metoprolol by food , 1977, Clinical pharmacology and therapeutics.
[38] W. D. Mason,et al. Pharmacokinetics of oxprenolol in normal subjects , 1976, Clinical pharmacology and therapeutics.
[39] N. Benowitz,et al. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. , 1980, Australian and New Zealand journal of medicine.
[40] J. LeLorier,et al. Bioavailabllity of lidocaine in normal volunteers and cirrhotic patients , 1978 .
[41] D. Weidler,et al. Ranitidine bioavailability and kinetics in normal male subjects , 1983, Clinical pharmacology and therapeutics.
[42] E. Perucca,et al. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. , 1979, British journal of clinical pharmacology.
[43] N. Benowitz,et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects , 1981, Clinical pharmacology and therapeutics.
[44] A. Mclean,et al. Interaction between oral propranolol and hydralazine , 1980, Clinical pharmacology and therapeutics.
[45] S. Walker,et al. The metabolism of salbutamol in man. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.
[46] R. Winkle,et al. Lorcainide disposition kinetics in arrhythmia patients , 1983, Clinical pharmacology and therapeutics.
[47] H. Mattie,et al. Rectal bioavailability of lidocaine in man: Partial avoidance of “first‐pass” metabolism , 1979, Clinical pharmacology and therapeutics.
[48] G. Kunos,et al. DISSOCIATION OF 5‐HYDROXYTRYPTAMINE EFFECTS ON MYOCARDIAL CONTRACTILITY AND CYCLIC AMP ACCUMULATION , 1974, British journal of pharmacology.
[49] R. Branch,et al. Biological determinants of propranolol disposition in man , 1978, Clinical pharmacology and therapeutics.
[50] T. Walle,et al. Propranolol glucuronide cumulation during long‐term propranolol therapy: A proposed storage mechanism for propranolol , 1979, Clinical pharmacology and therapeutics.
[51] T. Walle,et al. The predictable relationship between plasma levels and dose during chronic propranolol therapy , 1978, Clinical pharmacology and therapeutics.
[52] M. Kendall,et al. Effects of inflammatory disease on plasma oxprenolol concentrations. , 1979, British medical journal.
[53] P. Schulz,et al. Amitriptyline disposition in young and elderly normal men , 1983, Clinical pharmacology and therapeutics.
[54] P. G. Wells,et al. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long‐term dosing , 1983, Clinical pharmacology and therapeutics.
[55] A. Conney,et al. Decreased Concentration of Phenacetin in Plasma of Cigarette Smokers , 1972, Science.
[56] S. Bai,et al. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. , 1983, The Journal of pharmacology and experimental therapeutics.
[57] G. Tucker,et al. Systemic availability of orally administered meperidine , 1976, Clinical pharmacology and therapeutics.
[58] D. Roden,et al. Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man , 1984 .
[59] T. Taylor,et al. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. , 1977, Journal of pharmaceutical sciences.
[60] D. Drayer,et al. Pharmacologically Active Drug Metabolites: Therapeutic and Toxic Activities, Plasma and Urine Data in Man, Accumulation in Renal Failure , 1976, Clinical pharmacokinetics.
[61] G. Woody,et al. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene , 1982, Clinical pharmacology and therapeutics.
[62] R. Riccardi,et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.
[63] R. Brauer. Liver circulation and function. , 1963, Physiological reviews.
[64] A. Yacobi,et al. Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. , 1981, Journal of pharmaceutical sciences.
[65] H. Kostenbauder,et al. Isolated perfused rabbit lung as a model for intravascular and intrabronchial administration of bronchodilator drugs I:Isoproterenol. , 1982, Journal of pharmaceutical sciences.
[66] R. Dedrick,et al. Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.
[67] W. Jusko,et al. Factors affecting the absorption of riboflavin in man. , 1966, Journal of pharmaceutical sciences.
[68] C. von Bahr,et al. Effect of pentobarbital on the disposition of alprenolol , 1977, Clinical pharmacology and therapeutics.
[69] S. Bai,et al. Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. , 1982, The Journal of pharmacology and experimental therapeutics.
[70] C. Bahr,et al. Influence of pentobarbital on metoprolol plasma levels , 1979, Clinical pharmacology and therapeutics.
[71] D. Roden,et al. Antiarrhythmic activity of the O-demethyl metabolite of encainide. , 1982, The Journal of pharmacology and experimental therapeutics.
[72] D. Shand,et al. Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in man , 1973, Clinical pharmacology and therapeutics.
[73] J. Jonkman,et al. First-pass effect after rectal administration of thiazinamium methylsulfate. , 1979, Journal of pharmaceutical sciences.
[74] R. Winkle,et al. Clinical Pharmacology and Antiarrhythmic Efficacy of Encainide in Patients with Chronic Ventricular Arrhythmias , 1981, Circulation.
[75] J. Bircher,et al. Noninvasive assessment of portal-systemic shunting: Evaluation of a method to investigate systemic availability of oral glyceryl trinitrate by digital plethysmography , 1982 .
[76] L. Jackson,et al. Decreased first-pass metabolism of labetalol in chronic liver disease. , 1978, British medical journal.
[77] G. Tucker,et al. Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.
[78] P. Wilkinson,et al. Surgical catheterization of heptic-portal and peripheral circulations and maintenance in pharmacokinetic studies. , 1982, Journal of pharmaceutical sciences.
[79] M. Blanford,et al. Absence of metabolite in the disappearance of nitroglycerin following incubation with red blood cells , 1981 .
[80] R. Branch,et al. Propranolol Disposition in Chronic Liver Disease: A Physiological Approach , 1976, Clinical pharmacokinetics.
[81] Woods Sl,et al. Relative effectiveness of nitroglycerin ointment according to site of application. , 1979 .
[82] T. Blaschke,et al. Hepatic First-pass Metabolism in Liver Disease , 1979, Clinical pharmacokinetics.
[83] R. Vestal,et al. Inhibition of propranolol metabolism by chlorpromazine , 1979, Clinical pharmacology and therapeutics.
[84] E. Pritchett,et al. Comparison of intravenous and oral verapamil dosing , 1982, Clinical pharmacology and therapeutics.
[85] D. Geddes,et al. First pass uptake of 14C-propranolol by the lung. , 1979, Thorax.
[86] G. Kober,et al. Direct determination of hepatic extraction of verapamil in cardiac patients , 1981, Clinical pharmacology and therapeutics.
[87] C. Dollery,et al. METABOLISM OF ISOPRENALINE AFTER AEROSOL AND DIRECT INTRABRONCHIAL ADMINISTRATION IN MAN AND DOG , 1974, British journal of pharmacology.
[88] C. George. Drug Metabolism by the Gastrointestinal Mucosa , 1981, Clinical pharmacokinetics.
[89] N. Holford,et al. Stereoselective disposition and glucuronidation of propranolol in humans. , 1982, Journal of pharmaceutical sciences.
[90] U. Niederhauser,et al. Degradation of porstaglandin F2alpha in the human pulmonary circulation. , 1976, Thorax.
[91] E. Pritchett,et al. Reduced verapamil clearance during long‐term oral administration , 1981, Clinical pharmacology and therapeutics.
[92] S. Harapat,et al. Verapamil disposition kinetics in chronic atrial fibrillation , 1981, Clinical pharmacology and therapeutics.
[93] Shand Dg,et al. The disposition of propranolol. I. Elimination during oral absorption in man. , 1972 .
[94] M. Rowland,et al. Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.
[95] F. H. Tyler,et al. Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man. , 1969, The Journal of clinical endocrinology and metabolism.
[96] J. Wagner,et al. Prediction of steady‐state verapamil plasma concentrations in children and adults , 1982, Clinical pharmacology and therapeutics.
[97] C. Regårdh,et al. Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. , 1974, Life sciences.
[98] E. Kirsten,et al. The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses , 1982 .
[99] D. Edwards,et al. Clinical Pharmacokinetics of Pethidine: 1982 , 1982, Clinical pharmacokinetics.
[100] D. Greenblatt,et al. Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. , 1978, American Journal of Cardiology.
[101] T. Meinertz,et al. Lorcainide; II. Plasma concentration‐effect relationship , 1979, Clinical pharmacology and therapeutics.
[102] A. Poklis,et al. Pentazocine and tripelennamine (T's and Blues) abuse: toxicological findings in 39 cases. , 1982, Journal of analytical toxicology.
[103] G. Mundy,et al. Sodium salicylamide: Relative bioavailability and subjective effects , 1976, Clinical pharmacology and therapeutics.
[104] S. Dahl. Pharmacokinetics of methotrimeprazine after single and multiple doses , 1976, Clinical pharmacology and therapeutics.
[105] E. R. Garrett,et al. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. , 1978, International journal of clinical pharmacology and biopharmacy.
[106] A. Melander,et al. Influence of Food Intake on Presystemic Clearance of Drugs , 1983, Clinical pharmacokinetics.
[107] T. Walle,et al. 4‐Hydroxypropranolol and its glucuronide after single and long‐term doses of propranolol , 1980, Clinical pharmacology and therapeutics.
[108] D. Levin,et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. , 1978, Cancer research.
[109] L. Sheiner,et al. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. , 1981, British Journal of Clinical Pharmacology.
[110] P. Welling,et al. Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. , 1982, Journal of pharmaceutical sciences.
[111] M. Rowland,et al. Kinetics of Acetylsalicylic Acid Disposition in Man , 1967, Nature.
[112] C. Regårdh,et al. Clinical Pharmacokinetics of Metoprolol , 1980, Clinical pharmacokinetics.
[113] R. Wester,et al. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. , 1983, Journal of pharmaceutical sciences.
[114] S. Pond,et al. Effect of phenytoin on meperidine clearance and normeperidine formation , 1981, Clinical pharmacology and therapeutics.
[115] S. Brunk,et al. Morphine metabolism in man , 1974 .
[116] D. Kelly,et al. Verapamil kinetics in normal subjects and patients with coronary artery spasm , 1981, Clinical pharmacology and therapeutics.
[117] D. Schneck,et al. Mechanism by which hydralazine increases propranolol bioavailability , 1984, Clinical pharmacology and therapeutics.
[118] H. Szeto,et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. , 1977, Annals of internal medicine.
[119] C. Dollery,et al. Metabolism of isoprenaline in dog and man , 1972, British journal of pharmacology.
[120] C. Regårdh,et al. Pharmacokinetic and Pharmacodynamic Properties of Metoprolol in Patients with Impaired Renal Function , 1980, Clinical pharmacokinetics.
[121] N. Tygstrup,et al. Michaelis-Menten kinetics of galactose elimination by the isolated perfused pig liver. , 1976, The American journal of physiology.
[122] T. Inaba,et al. Metabolism of flurazepam by the small intestine , 1977, Clinical pharmacology and therapeutics.
[123] P. Meffin,et al. Clinical Pharmacokinetics Pethidine , 1978, Clinical pharmacokinetics.
[124] D. Shand,et al. Effect of route of administration on the relationship between β‐adrenergic blockade and plasma propranolol level , 1972, Clinical pharmacology and therapeutics.
[125] J. Rapoport,et al. Active metabolites of imipramine and desipramine in man , 1982, Clinical pharmacology and therapeutics.
[126] J. LeLorier,et al. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics , 1980, Clinical pharmacology and therapeutics.
[127] L. Gram,et al. First‐pass metabolism of nortriptyline in man , 1975, Clinical pharmacology and therapeutics.